Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Elacestrant Mechanism, Dosing, and Warnings
John explains elacestrant as an oral selective estrogen receptor degrader, dosing with food, CYP3A interactions, and lipid abnormalities.
Play episode from 11:14
Transcript
